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Abstract
Background and Aims: This was a safety and efficacy pharmacogenetic study of a previously performed randomized trial
which compared the effectiveness of treatment of hepatitis C virus infection with pegylated interferon alpha (pegIFNa) 2a
vs. 2b, both with ribavirin, for 48 weeks, in HCV-HIV coinfected patients.
Methods: The study groups were made of 99 patients (efficacy pharmacogenetic substudy) and of 114 patients (safety
pharmacogenetic substudy). Polymorphisms in the following candidate genes IL28B, IL6, IL10, TNFa, IFNc, CCL5, MxA, OAS1,
SOCS3, CTLA4 and ITPA were assessed. Genotyping was carried out using Sequenom iPLEX-Gold, a single-base extension
polymerase chain reaction. Efficacy end-points assessed were: rapid, early and sustained virological response (RVR, EVR and
SVR, respectively). Safety end-points assessed were: anemia, neutropenia, thrombocytopenia, flu-like syndrome,
gastrointestinal disturbances and depression. Chi square test, Student’s T test, Mann-Whitney U test and logistic regression
were used for statistic analyses.
Results: As efficacy is concerned, IL28B and CTLA4 gene polymorphisms were associated with RVR (p,0.05 for both
comparisons). Nevertheless, only polymorphism in the IL28B gene was associated with SVR (p = 0.004). In the multivariate
analysis, the only gene independently associated with SVR was IL28B (OR 2.61, 95%CI 1.2–5.6, p = 0.01). With respect to
safety, there were no significant associations between flu-like syndrome or depression and the genetic variants studied.
Gastrointestinal disturbances were associated with ITPA gene polymorphism (p = 0.04). Anemia was associated with OAS1
and CTLA4 gene polymorphisms (p = 0.049 and p = 0.045, respectively), neutropenia and thromobocytopenia were
associated with SOCS3 gene polymorphism (p = 0.02 and p = 0.002, respectively). In the multivariate analysis, the
associations of the SOCS3 gene polymorphism with neutropenia (OR 0.26, 95%CI 0.09–0.75, p = 0.01) and thrombocytopenia
(OR 0.07, 95%CI 0.008–0.57, p = 0.01) remained significant.
Conclusions: In HCV-HIV coinfected patients treated with PegIFNa and ribavirin, SVR is associated with IL28B rs8099917
polymorphism. HCV treatment-induced neutropenia and thrombocytopenia are associated with SOCS3 rs4969170
polymorphism.
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Introduction
Patients who are co-infected with hepatitis C virus (HCV)
within human immunodeficiency virus (HIV) are currently treated
on a 48-week regimen of pegylated interferon alpha (pegIFNa)
and ribavirin [1]. Although new antiviral agents that are active
against HCV are now available [2], they are just becoming to be
used for treating HCV-HIV co-infected patients. Response to the
treatment regimen varies greatly between individuals, as it does
between HCV-mono-infected individuals. Studies elsewhere have
identified several factors that can independently predict treatment
response: age, duration of the infection, HCV genotype, baseline
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plasma HCV viral load and the degree of liver fibrosis, among
others [3–5]. These factors, however, do not fully explain the
variability in the response to treatment, hence other factors, such
as host genetic background, have been sought [6,7].
Pharmacogenetics is the science that studies interindividual
variations in the response to and toxicity of drugs due to variations
in the genetic composition of individuals, in other words, how a
person’s genetic background influences the favourable or adverse
outcome of a certain treatment. Sufficient advances have been
made in this discipline to allow this fertile field of research to move
out of the research laboratory into the scenario of potential clinical
applications, including the treatment of HCV. In 2009, various
independent research teams provided evidence that the interleukin
28B (IL28B) rs12979860 and rs8099917 polymorphisms were
associated with spontaneous clearance of HCV [8] and with
sustained virological response to treatment with pegIFNa and
ribavirin [9–11] in HCV mono-infected patients. Further studies
have consistently confirmed these associations [12,13]. Similar
findings have also been reported in HCV-HIV co-infected patients
[14–17].
Recently, we carried out a randomised trial to compare the
efficacy and safety of the two available forms of pegIFNa plus
ribavirin in HCV-HIV co-infected patients [18]. No significant
differences in either efficacy or safety were found between the two
treatment arms. The present report is a pharmacogenetic substudy
of that study. Here we assess the possible relationship between the
efficacy and safety of pegIFNa plus ribavirin and polymorphisms
in the genes that encode for several proteins involved in the
metabolism of interferon a and ribavirin and in the defence
against viral infections.
Methods
Study design and patients
This was a pharmacogenetic substudy of the PegIFNa 2a vs.
PegIFNa 2b, both plus ribavirin, study (Clinical Trial Registry
Number: ISRCTN81765620. Registration Number in AEMPS:
03-0198), which was a prospective, multicentred, randomised,
open-label trial. Details of the study design and characteristics
have been reported elsewhere [18]. From the 182 patients
included in that trial, 123 had stored DNA available and
constitute the basis of the current pharmacogenetic study. Of
these patients, 10 had discontinued the study (2 voluntary and 8
protocol violation) and 14 had not completed the scheduled 48-
week treatment regimen because of discontinuation due to severe
adverse effects. Hence, 99 patients completed the study protocol
(or stopped it according to standart early virological stopping rules)
and had DNA available. The pharmacogenetic substudy of
efficacy was performed in these 99 individuals. For the pharma-
cogenetic substudy of safety we assessed these 99 patients plus the
14 who had discontinued treatment because of toxicity (n = 113).
Patients were evaluated before beginning treatment, 2 weeks after
initiation and every 4 weeks thereafter until cessation of therapy.
One last evaluation of the sustained viral response (SVR) was
made 24 weeks after cessation of therapy. A complete cell count
and routine biochemical tests including lactate were conducted at
every medical visit, together with a medical interview in order to
monitor possible secondary effects associated with treatment.
Ethics
Participants provided written informed consent before taking
part in the study. The institutional ethics committees of the
participating centres specifically approved this study. The full
names of the institutional review boards and committees are:
Comitè Ètic d’Investigació Clı́nica de l’Hospital Clinic (for the
Hospital Clinic, Barcelona, Spain), Comitè Ètic d’Investigació
Clı́nica de les Illes Balears (for the Hospital Son Llàtzer and the
Hospital Son Espases, from Palma de Mallorca, Spain) and
Comitè Ètic d’Investigació Clinica de l’Hospital Universitari de
Tarragona Joan XXIII (for the Hospital Joan XXIII, Tarragona
Spain). The study protocol was in accordance with the Declaration
of Helsinki of good clinical practice guidelines.
Assessment of efficacy
The primary measure of efficacy was SVR, which was defined
as undetectable plasma HCV-RNA at the end of the 24 week-
period of follow-up after cessation of the scheduled 48-week
treatment. Patients with detectable HCV-RNA after 24 weeks of
therapy were considered failures, and therapy was discontinued.
Secondary parameters of efficacy were: 1) early virological
response (EVR), defined as negative HCV-RNA or a $2 log
reduction of HCV-RNA from baseline at week 12 of treatment; 2)
rapid virological response (RVR), defined as negative HCV-RNA
at week 4 of treatment and, 3) relapses, defined as patients with
EVR but not SVR.
Assessment of safety
Adverse events were graded as mild, moderate, severe, or
potentially life-threatening according to a modification of the
World Health Organisation scale [19]. Therapy was permanently
discontinued in the face of life-threatening events. In cases of
haematological toxicity, the ribavirin or PegIFNa dose was
lowered according to the drug label recommendations and full
doses were restarted when the haematological data returned to the
normal level for that patient. The use of granulocyte-colony
stimulating factor and erythropoietin were permitted in this study
and used at the discretion of the physician responsible for each
patient, as was the use of antidepressant drugs. Anemia was
defined as haemoglobin level of ,10.5 g/dL. Neutropenia was
defined as a neutrophile count of less than 2.56109 cells/L.
Thrombocytopenia was considered when the platelet count fell
below 1256109 platelets/L. Patients suspected of suffering
depression were evaluated by a psychiatrist, and the presence/
absence of depression was assessed by the Structured Clinical
Interview for DSM-IV axis 1 Disorders (SCID) [20]. Adverse
gastrointestinal effects were considered if nausea, vomiting and/or
abdominal pain were present. Flu-like symptoms considered were
fatigue, fever, myalgia and headache.
Laboratory methods
Samples. After an overnight fast, 20 mL of blood was
collected from an antecubital vein into a VacutainerTM with
ethylene diamine tetra-acetic acid (EDTA). Five mL of whole
blood was used to determine CD4+ T-cell count. Five-hundred mL
was used for DNA isolation by a MagNa Pure LC Instrument
(Roche Diagnostics, Basel, Switzerland). Plasma and serum were
obtained by centrifugation at 3500 g for 15 min at 4uC.
Measurements. HCV infection was assessed by detection of
a positive anti-HCV antibody test in serum, through indirect
qualitative immunoassay (sandwich twice washed) (Advia Centaur,
Bayer Health Care, Tarrytown, NY). Plasma HCV viral load was
determined by a quantitative polymerase chain reaction assay
(Versant HCV-NA 3.0 {bDNA}, Siemens Medical Soluctions
Diagnostics, Tarrytown, NY). HCV genotyping was carried out as
previously described [21]. HIV-1 infection was diagnosed by a
positive enzyme-linked immunoabsorbent assay and confirmed by
a positive Western blot test. Plasma HIV-1 viral load was
determined by the Cobas amplicor HIV-1 Monitor Test v 1.5
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using the Cobas Amplicor system (Roche Diagnostics, City, State/
Country). CD4 T-cell count was assessed in a flow cytometer FAC
Scan (Becton Dickinson Immunocytometry Systems, San Jose,
CA). Data acquired was analysed using the Multiset program.
Genetic analyses. The nomenclature and details of the
single nucleotide polymorphisms (SNPs) assessed are shown in
Table 1. We selected to assess SNPs in genes encoding for: a)
several cytokines (IL28B, IL6, IL10, TNFa and IFNc) given that
they are involved in the host immune respose to HCV; b) the
chemokine CCL5, because of its expression is enhanced by HCV;
c) the proteins MxA, OAS1 and SOCS3, which regulate the
potent antiviral effect of interferon a; d) the cytotoxic lymphocyte
antigen CTLA4, that modulate the response of HCV to interferon
a, and; e) ITPA, since it has been associated with anemia in
patients treated with purine analogues. Genetic analyses were
carried out in the Centro Nacional de Genotipado (CeGen), Spain
(www.cegen.org). The methodology applied in the genotyping was
the single-base extension polymerase chain reaction Sequenom
iPLEX-Gold.
Statistical analysis
A descriptive analysis of the baseline variables was conducted.
Before statistical analysis, normality distribution and homogeneity
of the variables were tested by the Kolmogorov-Smirnov test.
Continuous variables were expressed as mean6SD or median
(interquartile range), depending on its distribution, and discrete
variables were expressed as percentage. Hardy-Weinberg equilib-
rium was assessed by the x2 goodness-of-fit test. Linkage
disequilibrium and haplotype analysis, after its reconstruction,
were made with the Haploview program [22]. The reconstruction
of haplotypes from genotype data of IL10, CTL4, IFN-c, OAS1,
CCL5 and ITPA genes was performed with the PHASE v 2.1
program [23,24]. Student’s T test was used to compare normally
distributed continuous variables with every type of virological
response (RVR, EVR and SVR) and with every category of
adverse effects. The Mann-Whitney U test was performed to
compare continuous variables that were not normally distributed.
Comparisons of qualitative variables, including genotype, allele
frequencies, clinical, analytical and therapy variables, with the
different types of virological response and with toxicity were
analyzed by the Chi-square test, and Fisher’s exact test when
necessary. Odds ratios and confidence intervals were calculated
using Woolf approximation. Logistic regression test was performed
to study predictive factors of sustained viral response and toxicity,
and only the variables with p,0.05 at univariate analysis were
included in the multivariate analysis. The variables included in the
multivariate models were selected by means of a forward-
backward stepwise procedure. All analyses were performed using
the SPSS/PC+ statistical package (V. 17.01 for Windows;
Chicago, IL). A p value of less than 0.05 was considered
significant, and all statistical tests were two tailed.
Results
Patients
Table 2 shows the main demographic and clinical character-
istics of the 123 patients that had DNA available, of the 99 patients
selected for the pharmacogenetic study of efficacy and of the 113
patients assessed for the pharmacogenetic study of safety.
Demographic and clinical characteristics of these 123 subjects
did not differ significantly from those of individuals who had not
stored DNA available (n = 59). Of note, there was a population
admixture regarding HCV genotypes (Table 2).
Efficacy analyses
Table 3 shows the association between the genotypes and alleles
assessed and each type of virological response. RVR was
associated with IL28B rs8099917 SNP, carriers of T allele had
the greater association with response, and with CTLA4 rs231775
SNP, carriers of the A allele were associated with better response.
No associations were observed with EVR. SVR was otherwise
associated with the IL28B rs8099917 SNP, carriers of the T allele
being associated with better outcome. After analysing the linkage
disequilibrium among the polymorphisms studied, only an
association between CCL5 rs2280789 and rs2107538 SNPs was
found (D9 = 1; 95%IC = 0.87–1). The reconstructed haplotypes of
these polymorphisms were not associated with SVR (p = 0.14).
Univariate analysis of SVR, which included several clinical,
virological and therapy variables, indicated that HCV genotypes
2+3, RVR and EVR, beaides of carriage of the IL28B rs8099917 T
allele, were significantly associated with SVR (Table 4). To
determine whether the IL28B rs8099917 SNP was independently
associated with SVR, we constructed a multivariate regression
model which included the variables reported to be significantly
associated with SVR in the univariate analysis. After adjustment
for other covariates, the IL28B rs8099917 T allele remained
significantly associated with SVR, compared with the G allele
(Table 5).
Safety analyses
Table 6 shows the association between the genotypes and alleles
assessed and the different categories of adverse effects defined.





















Nomenclature (acronyms in parentheses): interleukin 28B (IL28B), interleukin 6
(IL6), interleukin 10 (IL10), tumor necrosis factor alpha (TNFa), interferon gamma
(IFNc), chemokine C ligand 5 (CCL5*), myxovirus resistance protein A (MxA),
oligoadenyl synthase 1 (OAS1), suppressor of cytokine signalling 3 (SOCS3),
cytotoxic T lymphocyte antigen 4 (CTLA4), inosine triphosphatase (ITPA).
*Formerly known as: regulated upon activation normally expressed and
secreted (RANTES).
doi:10.1371/journal.pone.0047725.t001
Pharmacogenetics of HCV Treatment in HIV+ Patients
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e47725
There were no significant associations between flu-like syndrome
or depression and any of the genetic variants studied. Adverse
gastrointestinal disturbances were associated with the ITPA
rs1127354 polymorphism. Anemia was associated with the OAS1
rs2660 and the CTL4 rs231775 polymorphisms, and neutropenia
and thrombocytopenia were associated with the polymorphism
rs4969170 in the SOCS3 gene.
We performed an univariate analysis of the association of the six
categories of adverse effects defined and the clinical, virological
and therapy variables that were assessed in the safety substudy (the
variables used are detailed in Table 4). Among continuous
variables, the significant associations observed were: flu-like
syndrome with higher weight (71.1612.7 vs. 65.269 k.;
p = 0.02); depression with higher HIV plasma viral load (median
199 copies/mL, 25–75% IQR 49–298 vs. median 49 copies/mL,
25–75% IQR 39–199; p = 0.045), neutropenia with lower CD4 T-
cell count (median 508 cells/mL, 25–75% IQR 340–769 vs.
median 591 cells/mL, 25–75% IQR 497–800; p = 0.03) and
thrombocytopenia with lower CD4 T-cell count (median 511
cells/mL, 25–75% IQR 383–704 vs. non neutropenic: median
Table 2. Main demographic and clinical characteristics of the groups studied.
All patients (n = 123) Efficacy study (n = 99) Safety study(n = 113)
Male gender (%) 74.8 74.7 74.3
Age (years)* 41 (38–43) 40 (38–43) 40 (38–43)
Baseline weight (Kg)** 69.3612 69.5612 69.3612
Baseline height (cm)** 170.768.2 170.968.4 170.768.3
HCV/HIV acquiring risk factor (%) IDU 74 72.7 72.6
Heterosexual 17.1 18.2 17.7
Male homosexual 5.7 6.1 6.2
Haemophiliac 0.8 1 0.9
Other 2.4 2 2.7
AIDS (%) 42.2 40.4 42.5
HCV genotype (%) 1 43.9 45.4 44.2
2 3.3 3 3.5
3 34.1 32.3 32.7
4 18.7 19.2 19.4
Baseline HCV-RNA.400000 IU/mL (%) 78.3 77.1 77.3
Baseline HCV-RNA.600000 IU/mL (%) 60 58.3 60
Baseline HCV-RNA.800000 IU/mL (%) 57.5 55.2 57.3
Fibrosis score, (%) 0–1 34.9 35.7 35.1
2–4 65.1 64.3 64.9
Steatosis (%) 34 28.6 34.1
Baseline CD4 cell count (cells/mL)* 551 (430–733) 562 (434–760) 562 (415–787)
Baseline CD4 cell count #350 cells/mL (%) 14.8 15.3 16.2
Baseline HIV viral load#200 copies/mL (%) 78.7 75.5 77.7
HAART (%) 84.5 82.8 84.1
RVR (%) 38.4 35.4 36.3
EVR (%) 75.4 73.9 74.7
SVR (%) 49.6 51.5 50
Discontinuation for toxicity (%) 11.4 0 12.8
Toxicity (%) 92.7 90.9 92
Anemia (%) 28.5 28.3 26.5
Neutropenia (%) 39.8 40.4 40.7
Thrombocytopenia (%) 39 38.4 39.8
Flu-like syndrome (%) 69.1 69.7 68.1
Headache (%) 15.4 16.2 15.9
Depression (%) 32.5 32.3 33.6
Gastrointestinal symptoms (%) 24.4 26.3 24.8
Lactic acidosis (%) 4.1 2 3.5
*Median (25–75% interquartile range).
**Mean6standard deviation.
HAART: Highly active antiretroviral therapy. EVR: Early virological response. RVR: Rapid virological response. SVR: Sustained virological response.
doi:10.1371/journal.pone.0047725.t002
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611 cells/mL, 25–75% IQR 473–816; p = 0.049). Among
categoric variables, the only significant associations observed
were: neutropenia with pegIFNa 2a vs. 2b (OR 2.6, 95CI 1.2–5.7,
p = 0.01), and with female vs. male gender (OR 2.7, 95%CI 1.1–
6.4, p = 0.02); and thrombocytopenia with pegIFNa 2a vs. 2b (OR
2.9, 95%CI 1.3–6.3, p = 0.008).
For multivariate analyses, we constructed a logistic regression
model which included the adverse effects categories that were
associated with more than one clinical, analytical, virological or
genetic variable in the univariate analysis. The only adverse effects
that fulfilled these criteria were neutropenia and thrombocytope-
nia. With respect to neutropenia we constructed a multivariate
regression model which included the following variables: gender,
type of pegIFNa prescribed, CD4 cell count stratified in two
categories (#350 and .350 cells/mL) and SOCS3 rs4969170
genotype. The use of pegIFNa 2a and CD4 cell count #350 cells/
mL was associated with greater risk of neutropenia while carriers
of the SOCS3 rs4969170 AG genotype had significantly lower risk
of neutropenia. Regarding thrombocytopenia, the model included
the type of pegIFNa prescribed, stratified CD4 cell count, and
SOCS3 rs4969170 genotype. Patients treated with pegIFNa 2a had
significantly higher risk of thrombocytopenia, and carriers of the
SOCS3 rs4969170 AA genotype had significantly lower risk of
thrombocytopenia (Table 7).
Discussion
Given that HCV treatment is of long duration, has potentially
serious adverse effects and is expensive, several attempts have been
made to identify the factors that predict a successful outcome [3–
5]. Our previous study identified that factors associated with
treatment outcome are: age, HCV viral load and HCV genotype
[18]. This pharmacogenetic substudy shows that the IL28B
rs8099917 polymorphism is associated with SVR to hepatitis C
therapy in HCV-HIV co-infected patients and therefore confirms
the results that have been reported in many other studies
performed in HCV mono-infected [9–13] and in HCV-HIV co-
infected patients [14–17]. A new finding from our study is the
association between HCV treatment-induced neutropenia and
Table 3. Association between the different types of virological response and the genetic variants assessed.
Genotype/allele RVR (n = 35) EVR (n = 73) SVR (n = 51)
OR (95%CI) p OR (95%CI) p OR (95%CI) p
IL28B rs8099917 TT 1 1 1
GT 0.41 (0.14–1.23) 0.1 0.42 (0.15–1.21) 0.25 0.35 (0.14–0.87) 0.01
GG 0 0.44 (0.04–5.39) 0
T 2.8 (1.1–7.58) 0.03 1.9 (0.84–4.46) 0.12 3.1 (1.41–6.79) 0.004
CTLA4 rs231775 AA 1 1 1
AG 0.29 (0.09–1) 0.03 0.78 (0.27–2.21) 0.46 0.36 (0.08–1.72) 0.23
GG 0.13 (0.01–1.11) 3 (0.33–26.79) 0.74 (0.16–3.35)
A 3.6 (1.44–9) 0.004 0.8 (0.37–1.76) 0.6 1.16 (0.6–2.27) 0.66
RVR: Rapid virological response. EVR: Early virological response. SVR: Sustained virological response. OR: Odds ratio. CI: confidence interval.
Odds ratio in the different genotypes are referred to the genotype with OR = 1. The value ‘‘0’’ means that there were no subjects carrying this genotype.
Note: the remaining genetic variants assessed showed no significant associations with RVR, EVR and SVR (p.0.05 for all comparisons).
doi:10.1371/journal.pone.0047725.t003
Table 4. Association of clinical, biochemical, and therapeutic
factors with SVR in patients who completed the scheduled 48-
week treatment regimen with pegIFNa and ribavirin.
Variables Odds ratio 95% CI p
Male vs. female 2.33 0.91–5.96 0.07
Age #40 vs. .40 years 2.17 0.97–4.85 0.06
Weight,75 vs. $75 Kg 0.48 0.19–1.18 0.1
CDC stage B vs. A 0.66 0.2–2.17 0.49
CDC stage C vs. A 0.42 0.14–1.26 0.12
HIV viral load,200 vs. $200 copies/mL 1.39 0.55–3.5 0.48
HAART (yes vs. no) 0.9 0.33–2.66 0.9
ABC (yes vs. no) 1.46 0.5–4.17 0.48
HCV RNA.800000 vs. #800000 IU/mL 0.9 0.4–2.02 0.8
HCV RNA.600000 vs. #600000 IU/mL 0.69 0.3–1.56 0.37
HCV RNA.400000 vs. #400000 IU/mL 0.54 0.2–1.44 0.22
HCV genotype 2+3 vs. 1+4 4.65 1.85–11.6 0.001
Fibrosis 2–4 vs. 0–1 1.35 0.56–3.3 0.5
Steatosis (yes vs. no) 1.39 0.31–6.14 0.7
CD4#350 cells/mL 2.96 0.87–10 0.07
EVR (yes vs. no) .999.999 ,0.001
RVR (yes vs. no) 31.2 6.56–148.37 ,0.001
pegIFNa 2a vs pegIFNa 2b 1.4 0.65–3.17 0.37
pegIFNa: pegylated interferon alpha. CI: confidence interval. CDC: Centers for
Disease Control.
HAART: highly active antiretroviral therapy. ABC: abacavir. EVR: early virological
response. RVR: rapid virological response.
doi:10.1371/journal.pone.0047725.t004
Table 5. Independent predictors of SVR in patients who
completed the scheduled 48-week treatment regimen with
pegIFNa and ribavirin.
Variables Odds ratio 95% CI p
IL28B T vs. G allele 2.61 1.2–5.6 0.01
HCV Genotype 2+3 vs. 1+4 3.61 1.98–6.58 ,0.001
SVR: sustained virological response. pegIFNa: pegylated interferon alpha. CI:
confidence interval.
doi:10.1371/journal.pone.0047725.t005
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thrombocytopenia and the SOCS3 rs4969170 polymorphism.
As far as cytokines are concerned and besides IL28B, we have
assessed the effect of polymorphism in genes encoding for diverse
cytokines, such as IL6, IL10, TNFa and IFNc, given that they are
involved in the immunological response to HCV [6,7,25,26]. The
genes that encode for these cytokines are polymorphic and genetic
variants may have functional significance at the protein level.
Despite this, our data do not show any significant associations
between IL6, IL10, TNFa and IFNc polymorphisms and virological
response to treatment with pegIFNa and ribavirin. Our results
agree, therefore, with the lack of association found between
polymorphism in these cytokine-encoding genes and virological
response to HCV treatment [27–29]. Nevertheless, the data from
the present study do not confirm the positive association between
virological response and IL6 [7] and IL10 [6,30] polymorphisms.
The reasons for this discrepancy may be due to the low number of
patients assessed in some investigations [6,7,30] as well as in the
current study, which means unstable and, often, non-replicable
data. Differences in the type of population assessed (HCV mono-
infected vs. HCV-HIV co-infected) and in the type of HCV
treatment used (interferon monotherapy vs. pegIFNa plus
ribavirin) may offer additional explanation.
With respect to chemokines, we have assessed CCL5. The
expression of CCL5 is enhanced in liver and in blood by HCV and
successful HCV treatment supressess this upregulation [31].
Previous studies in HCV monoinfected patients have shown that
CCL5 rs2107538 SNP and some CCL5 haplotypes are associated
with HCV treatment response [32,33] although data are
inconsistent [34]. Of note, several patients in these studies were
treated with standard interferon a rather than with pegIFNa. The
current study is the first one performed in HCV-HIV coinfected
subjects and our data suggest no relationship between CCL5 gene
polymorphisms and SVR. Haplotyping confirmed this lack of
association. Differences between our results and those provided by
other investigations [32,33] may be searched in the population
assessed (HCV monoinfected vs. HCV-HIV coinfected) and/or in
the type of interferon used (standart interferon a vs. pegIFNa).
Furthermore, no association was observed between CCL5 gene
polymorphisms and the different types of adverse effects assessed.
We also assessed the role of polymorphisms in the interferon
pathway given that IFNa increases the expression of several genes
involved in the immunological response to HCV [35]. IFNa has a
potent antiviral action that is exerted indirectly through a complex
mechanism [36] in which the myxovirus resistance protein A
(MxA), the oligoadenylate synthase 1 (OAS1) and the suppressor
of cytokine signaling 3 (SOCS3) are involved [37]. The genes that
encode for MxA, OAS1 and SOCS3 are polymorphic and it has
been assessed whether polymorphism in these genes modulate the
response to interferon in HCV monoinfected subjects [38,39]. The
SOCS3 2487A allele increases SOCS3 expression and was
associated with pegIFNa and ribavirin HCV treatment failure
[38]. Furthermore, carriage of the MxA 288G.T allele, was
associated with a better response of HCV to interferon and
polymorphism located in OAS1 gene was shown to be associated
with spontaneous HCV clearance [39]. Our data in the current
study in HCV-HIV coinfected subjects indicates that MxA, OAS1
and SOCS3 SNPs are not associated with HCV treatment efficacy
and therefore confirm the results of previous investigations [40]. A
new finding from our study was the association of the SOCS3
rs4969170 polymorphism with HCV treatment-induced neutro-
penia and thrombocytopenia. Plausible biological explanation can
be searched in the fact that in studies in knockout mice, SOCS3
has been shown to be implicated in both granulopoiesis [41] and
thrombopoiesis [42].
CTLA4 is a polypeptide involved in the processing of antigens
by T-cell lymphocytes and influences the response of HCV to
interferon. Three studies have assessed the relationship between
the polymorphisms rs231776 (+49A.G) and rs5247909
(2318C.A) in the CTLA4 gene and HCV treatment response,
either in HCV monoinfected patients [43,44] and in HCV/HIV
co-infected individuals [45]. Despite some discrepancies regarding
the effect of gender or the type of interferon a used, data from
these studies were consistent with an association between the two
polymorphsms assessed and SVR. This association was particu-
larly robust in carriers of the +49 GG genotype [45]. Our data do
not replicate this findings since we found no significant associations
between polymorphism in the CTLA4 gene and SVR. Reasons for
discrepancy may be seek in the lower number of patients in our
study compared with that of other investigations, which suggest
underpower. Genuine population differences may offer an
additional explanation.
Polymorphism in the ITPA gene has been related with a benign
erythrocyte enzymopathy, which is characterized by the accumu-
lation of ITP in red cells. The affected patients may develop
anemia when they are treated with purine analogues. Ribavirin is
a purine analogue and previous studies have shown that ITPA
genetic variants leading to ITPA deficiency are associated with
ribavirin-induced anemia in HCV-treated patients [46]. This
association has been replicated in studies performed in HCV-
monoinfected [47–50] and in HCV-HIV co-infected [51] patients.
In our Spanish cohort, however, we were unable to reproduce
these findings, since no significant associations were observed
Table 7. Independent predicitive factors of adverse effects.
Neutropenia Thrombocytopenia
OR (95%CI) p OR (95%CI) p
PegIFNa 2a vs. 2b 4.23 (1.59–11.23) 0.04 2.62 (1.91–6.29) 0.03
Female vs. male 2.51 (0.94–6.74) 0.07 * *
CD4 cell count #350 vs. .350 cells/mL 4.69 (1.29–17.24) 0.02 1.94 (0.58–6.49) 0.28
SOCS3 rs4969170 GG 1 1
AG 0.26 (0.09–0.75) 0.01 0.75 (0.31–1.83) 0.53
AA 1.1 (0.28–3.9) 0.94 0.07 (0.008–0.57) 0.01
OR: odds-ratio. CI: Confidence interval. pegIFNa: pegylated interferon alpha.
*Gender was not included in multivariate analysis of thrombocytopenia, because in the univariate analysis this variable did not fulfill criteria for inclusion in the
multivariate analysis.
doi:10.1371/journal.pone.0047725.t007
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between the two ITPA gene variants assessed and ribavirin-
induced anemia and/or the need of ribavirin dose reduction.
Additionally, we failed to find any significant association between
ITPA SNPs and neutropenia. Also, we did not find associations
between ITPA polymorphisms and thrombocytopenia, a finding
that has been reported in two independent cohorts [52,53]. As
virological response is concerned, our data do not suggest any
association between ITPA genetic variants and virological
response. Our data therefore agrees with that reported by
Chayama et al. [54], but differs markedly from that provided by
Ochi [47] and Kurosaki [55]. It is unlikely that population
differences could explain this discrepancy, since these three studies
have been performed in Japanese.
We acknowledge that our work has some limitations that should
be taken into account when interpreting the data. The number of
patients assessed is low for a genetic association analysis and this
may render our study underpowered for finding some significant
associations. We believe, however, that studies performed with a
phenotypically well-defined population such as ours may provide
useful material for performing meta-analyses which could over-
come issues of small sample size. Additionally, our cohort had a
mixture of HCV genotypes. Since HCV genotype is a strong
determinant of HCV treatment response, this could be a bias in
our study. Despite these limitations, this is the first pharmacoge-
netic study arising from a randomised clinical trial performed in
HCV-HIV co-infected patients and we believe that this design
gives additional value to our findings.
In summary, in HCV-HIV co-infected patients treated with
PegIFNa and ribavirin, SVR is associated with IL28B rs8099917
polymorphism. Neutropenia and thrombocytopenia are associated
with SOCS3 r4969170 polymorphism.
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